Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus ORETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus ORETON.
DELATESTRYL vs ORETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Androgen receptor agonist; binds to androgen receptors, stimulating protein synthesis, growth of male reproductive tissues, and development of secondary sexual characteristics.
50 to 200 mg intramuscularly every 2 to 4 weeks.
Testosterone enanthate 50-400 mg IM every 2-4 weeks.
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
8 hours for testosterone; clinical context: requires daily or weekly dosing for replacement therapy
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Renal (90% as metabolites, 5% unchanged), biliary/fecal (10%)
Category C
Category C
Androgen
Androgen